TMEM106B Lysosomal Restoration Therapy for Neurodegeneration

TMEM106B Lysosomal Restoration Therapy for Neurodegeneration

Pathway Diagram

```mermaid
flowchart TD
TMEM106B["TMEM106B"]
endolyso["Endosome-Lysosome Function"]
GRN["GRN Progranulin"]
C9ORF72["C9ORF72"]
PSEN1["PSEN1"]
TAU["TAU Protein"]
LRRK2["LRRK2"]
aging["Aging Process"]
alzheimer["Alzheimer Disease"]
als["Amyotrophic Lateral Sclerosis"]
dementia["Frontotemporal Dementia"]
parkinson["Parkinson Disease"]
neurodegeneration["Neurodegeneration"]

TMEM106B -->|"regulates"| endolyso
TMEM106B -->|"associated with"| GRN
TMEM106B -->|"associated with"| C9ORF72
TMEM106B -->|"regulates"| PSEN1
TMEM106B -->|"regulates"| TAU
TMEM106B -->|"regulates"| LRRK2
TMEM106B -->|"associated with"| aging
endolyso -->|"dysfunction leads to"| neurodegeneration
GRN -->|"deficiency promotes"| dementia
C9ORF72 -->|"mutations cause"| als
PSEN1 -->|"mutations cause"| alzheimer
TAU -->|"aggregation in"| alzheimer
LRRK2 -->|"mutations cause"| parkinson
aging -->|"promotes"| neurodegeneration
neurodegeneration -->|"manifests as"| alzheimer
neurodegeneration -->|"manifests as"| als
neurodegeneration -->|"manifests as"| dementia
neurodegeneration -->|"manifests as"| parkinson

classDef central fill:#006494
classDef protective fill:#1b5e20
classDef pathological fill:#ef5350
classDef regulatory fill:#4a1a6b
classDef outcome fill:#5d4400

class TMEM106B central
class endolyso,GRN protective
class aging,neurodegeneration pathological

TMEM106B Lysosomal Restoration Therapy for Neurodegeneration

Pathway Diagram

Overview

TMEM106B Lysosomal Restoration Therapy is a therapeutic strategy targeting the TMEM106B protein to restore lysosomal function in frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and related neurodegenerative diseases. TMEM106B is a major genetic risk factor for FTLD-TDP and influences lysosomal trafficking, lipid metabolism, and microglial function.

Genetic Rationale

TMEM106B polymorphisms represent one of the strongest genetic risk factors for FTLD-TDP:

• Risk variant (rs1990622): Common variant associated with ~2-3x increased FTLD risk[@nicholson2020]
• FTLD-GRN: TMEM106B modifies disease onset and severity in progranulin mutation carriers[@baker2006]
• ALS: TMEM106B risk variants associated with earlier disease onset
• Mechanism: The risk variant leads to reduced TMEM106B expression and lysosomal dysfunction

Disease Coverage

| Disease | Coverage | Rationale |
|---------|----------|-----------|
| FTLD | 10 | Primary genetic risk factor; TDP-43 pathology |
| ALS | 9 | TMEM106B modifies ALS onset; TDP-43 overlap |
| PD | 6 | Lysosomal dysfunction contributes to alpha-synuclein |
| AD | 5 | Lysosomal impairment in amyloid processing |
| Aging | 8 | Age-related lysosomal decline |

Mechanism of Action

TMEM106B is a lysosomal transmembrane protein that regulates:

Therapeutic Approach

The therapeutic strategy involves multiple modalities:

1. Gene Therapy (AAV-TMEM106B)

• Deliver wild-type TMEM106B to restore expression levels
• Use neuronal and microglial promoters for cell-type specificity
• Target the basal ganglia and frontal cortex

• Develop compounds that increase TMEM106B expression
• Target TFEB/TEA domain transcription factors
• Screen for lysosomal function enhancers

• V-ATPase modulators to improve acidification
• Autophagy enhancers to support clearance
• Lipid metabolism modulators

• TMEM106B + progranulin restoration (for GRN mutation carriers)
• TMEM106B + autophagy enhancement
• TMEM106B + TDP-43 aggregation inhibitors

Scoring Rubric

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | New target class; TMEM106B not yet targeted therapeutically |
| Mechanistic Rationale | 9 | Strong genetics; lys dysfunction is root cause |
| Root Cause Targeting | 9 | Addresses TMEM106B haploinsufficiency directly |
| Delivery | 7 | AAV viable; small molecules challenging |
| Safety | 8 | TMEM106B overexpression likely safe (brain expresses it) |
| Combinability | 8 | Synergizes with GRN and autophagy approaches |
| Biomarker Potential | 7 | CSF progranulin, lysosomal function markers |
| De-risking Path | 7 | iPSC neurons, mouse models available |

Total Score: 71/100

Biomarkers

• Fluid: CSF progranulin, NfL, phosphorylated TDP-43
• Imaging: Lysosomal PET ligands, volumetric MRI
• Functional: Lysosomal pH measurements in patient-derived cells

Development Pipeline

Phase 1: Target Validation

• Validate TMEM106B expression in FTLD/ALS patient iPSC neurons
• Confirm lysosomal function rescue with TMEM106B overexpression

Phase 2: Therapeutic Screening

• AAV vector development for TMEM106B
• Small molecule library screening for expression enhancers

Phase 3: Clinical Translation

• Establish biomarker correlates
• Design FTLD/ALS enrichment trials

References

See Also

• [ABI3 Gene](/wiki/genes-abi3) — associated_with
• [ACE Gene](/wiki/genes-ace) — associated_with
• [adam17](/wiki/genes-adam17) — associated_with
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — associated_with
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — causes
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — increases_risk
• [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — associated_with
• [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — causes

Pathway Diagram

The following diagram shows the key molecular relationships involving TMEM106B Lysosomal Restoration Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis: